Chris Watson

Title: Chris Watson - Innovator in Preeclampsia Biomarkers

Introduction

Chris Watson is a notable inventor based in Belfast, GB. He has made significant contributions to the field of medical diagnostics, particularly in the area of preeclampsia. His innovative work focuses on the use of biomarkers to predict the risk of this serious condition in pregnant women.

Latest Patents

Watson holds a patent for a groundbreaking invention titled "Biomarker for Preeclampsia." This invention relates to the use of leucine-rich alpha 2 glycoprotein 1 (LRG1) as a biomarker for preeclampsia, applicable from the first trimester of pregnancy. Elevated levels of LRG1 can indicate the risk of developing preeclampsia or other hypertensive disorders during pregnancy. The predictive test involves measuring LRG1 protein, peptide fragments, DNA, or RNA from various biological samples, including blood, plasma, serum, urine, saliva, or amniotic fluid. This invention provides a method and a test kit to assess the risk of preeclampsia in pregnant women, utilizing antibodies to measure LRG1 levels in samples. Watson's patent is a significant advancement in prenatal care, with 1 patent to his name.

Career Highlights

Chris Watson is affiliated with The Queen's University of Belfast, where he conducts research and develops innovative solutions in medical diagnostics. His work has garnered attention for its potential to improve maternal and fetal health outcomes.

Collaborations

Watson collaborates with esteemed colleagues, including Timothy Lyons and Alice Cheung, to further advance research in the field of biomarkers and prenatal diagnostics.

Conclusion

Chris Watson's contributions to the field of preeclampsia biomarkers represent a significant step forward in prenatal care. His innovative approach has the potential to enhance the early detection and management of this serious condition, ultimately improving health outcomes for mothers and their babies.